Robert L. Hudkins - Concepedia

Author

Robert L. Hudkins

Also Known As

Hudkins, R.L., Hudkins, Robert, John Isaacs, R. Hudkins, R. L. HUDKINS, R.L. Hudkins, Robert Hudkins, Robert L Hudkins, Robert L. Hudkins

125

Publications

2.8K

Citations

H-Index

Concepts

All Affiliations

Teva Pharmaceuticals (United States)Brandywine Photonics (United States)Avalon Pharma (United States)Virginia Commonwealth University Medical Center

About

Robert L. Hudkins is an author at Teva Pharmaceuticals (United States) specializing in medicine, drug discovery, and pharmacology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	17	35	1.3K
2	Natural Sciences	15	20	937
3	Biochemistry	15	22	516
4	Engineering	2	2	113
5	Social Sciences	1	1	36

Robert L. Hudkins

Publications

2.1K

Citations

H-Index

Page 1

	Year	Citations
Knowledge-Based, Central Nervous System (CNS) Lead Selection and Lead Optimization for CNS Drug Discovery Arup K. Ghose, Torsten Herbertz, Robert L. Hudkins, ACS Chemical Neuroscience Cns Drug DiscoveryPharmaceutical ResearchDrug TargetHit IdentificationLead Identification	2011	432
Neurotrophic 3,9-Bis[(alkylthio)methyl]- and -Bis(alkoxymethyl)-K-252a Derivatives Masami Kaneko, Yutaka Saito, Hiromitsu Saito, Journal of Medicinal Chemistry	1997	119
The selective poly(ADP-ribose) polymerase-1(2) inhibitor, CEP-8983, increases the sensitivity of chemoresistant tumor cells to temozolomide and irinotecan but does not potentiate myelotoxicity Sheila Miknyoczki, Hong Chang, Jennifer V. Grobelny, Molecular Cancer Therapeutics	2007	110
Anaplastic lymphoma kinase activity is essential for the proliferation and survival of anaplastic large-cell lymphoma cells Weihua Wan, Mark S. Albom, Lihui Lü, Blood	2005	105
Synthesis Of 2-Aryl- and 2-Vinyl-1H-indoles via Palladium-Catalyzed Cross-Coupling of Aryl and Vinyl Halides with 1-Carboxy-2-(tributylstannyl)indole Robert L. Hudkins, James L. Diebold, Frank D. Marsh The Journal of Organic Chemistry Cross-coupling ReactionEngineeringDonut IconNatural SciencesDiversity-oriented Synthesis	1995	95
Mixed lineage kinase activity of indolocarbazole analogues Chikara Murakata, Masami Kaneko, George Gessner, Bioorganic & Medicinal Chemistry Letters Receptor Tyrosine KinaseIndolocarbazole AnaloguesDrug DiscoverySystems Biology	2002	93
A New Class of Potent Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors: Structure−Activity Relationships for a Series of 9-Alkoxymethyl-12-(3-hydroxypropyl)indeno[2,1-<i>a</i>]pyrrolo[3,4-<i>c</i>]carbazole-5-ones and the Identification of CEP-5214 and Its Dimethylglycine Ester Prodrug Clinical Candidate CEP-7055 Diane E. Gingrich, D. Rajagopala Reddy, Mohamed Iqbal, Journal of Medicinal Chemistry PharmacotherapyMedicinal ChemistryAngiogenesisFibroblast Growth FactorTyrosine Kinase Inhibitors	2003	74
Discovery and Characterization of 6-{4-[3-(<i>R</i>)-2-Methylpyrrolidin-1-yl)propoxy]phenyl}-2<i>H</i>-pyridazin-3-one (CEP-26401, Irdabisant): A Potent, Selective Histamine H<sub>3</sub>Receptor Inverse Agonist Robert L. Hudkins, Rita Raddatz, Ming Tao, Journal of Medicinal Chemistry	2011	68
Covalent Docking Identifies a Potent and Selective MKK7 Inhibitor Amit Shraga, Evgenia Olshvang, Natalia Davidzohn, Cell chemical biology Drug TargetMedicinePharmacologyRational Drug DesignMolecular Docking	2018	63
CEP-26401 (Irdabisant), a Potent and Selective Histamine H3 Receptor Antagonist/Inverse Agonist with Cognition-Enhancing and Wake-Promoting Activities Rita Raddatz, Robert L. Hudkins, Joanne R. Mathiasen, Journal of Pharmacology and Experimental Therapeutics	2011	58

Page 1